WITHDRAWN: Splenic Artery Embolization (SAE) for Refractory Ascites (RA) in the Post-liver Transplant Patient: A Case Report and Brief Review of the Literature

Author(s):  
Jason Salsamendi ◽  
Keith Pereira ◽  
Susan Williams ◽  
Ji Fan ◽  
Govindarajan Narayanan
2008 ◽  
Vol 10 (2) ◽  
pp. 117-122 ◽  
Author(s):  
T. Van Schooneveld ◽  
A. Freifeld ◽  
B. Lesiak ◽  
A. Kalil ◽  
D.A. Sutton ◽  
...  

2012 ◽  
Vol 34 (2) ◽  
pp. 269-271 ◽  
Author(s):  
Alessio Provenzani ◽  
Monica Notarbartolo ◽  
Manuela Labbozzetta ◽  
Paola Poma ◽  
Adele D’Antoni ◽  
...  

2006 ◽  
Vol 130 (1) ◽  
pp. 93-96
Author(s):  
Joan E. Etzell ◽  
Endi Wang

Abstract Pelger-Huët anomaly is a congenital or acquired abnormality of neutrophil nuclear segmentation. The acquired form may be a result of a clonal myeloid malignancy, such as myelodysplastic syndrome, or may be a secondary nonclonal change related to a variety of underlying causes, including infections and medications. We report a case of a 56-year-old man who developed acquired Pelger-Huët anomaly following liver transplantation while on the immunosuppressive agents tacrolimus and mycophenolate mofetil. These medications have been reported in association with this abnormality, but usually as a single agent or in combination with other drugs. In our case, the Pelger-Huët anomaly may be the result of the combination of these 2 drugs or mycophenolate alone with subsequent desensitization because resolution of the abnormality occurred after a reduction in mycophenolate mofetil dose, and the abnormality did not recur when mycophenolate mofetil was increased to a dose previously associated with Pelger-Huët anomaly during the time that tacrolimus was discontinued.


2019 ◽  
Vol 51 (5) ◽  
pp. 1621-1624 ◽  
Author(s):  
G.S. Arantes Ferreira ◽  
A.L.C. Watanabe ◽  
N.C. Trevizoli ◽  
F.M.F. Jorge ◽  
G.O.N. Cajá ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document